The autoimmune response to IGF2BP2 observed in hepatocellular carcinoma and colorectal, ovarian, and breast cancers supports the potential of autoantibodies against IGF2BP2 as biomarkers for cancer screening, diagnosis, and prognosis [5]. The gene discussed is IGF2BP2; the disease is cancer.